Showing 111-120 of 797 results for "".
Emerging Research: Epilepsy and Behavioral/Intellectual Disabilities and the Challenge of SUDEP
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/emerging-research-epilepsy-and-behavioralintellectual-disabilities-and-the-challenge-of-sudep/30569/Researchers shared new findings at the AES meeting this winter.Global Outcomes Data and Possible New Therapies in the Huntington's Pipeline
https://practicalneurology.com/diseases-diagnoses/movement-disorders/global-outcomes-data-and-possible-new-therapies-in-the-huntingtons-pipeline/30606/Researchers are focused on patient outcomes on a global scale and join clinicians in the vigil for new drug approvals.Preserving Memory: Tips to Help Baby Boomers Stay in the Game
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/PN0309_03-php/30934/Middle-aged patients may unnecessarily fear dementia. These 10 tips can help preserve cognitive function.On the Role of Caregivers in Epilepsy Treatment
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/on-the-role-of-caregivers-in-epilepsy-treatment/32065/A Discussion with Greg Grunberg, Host of the “The Care Giver” SeriesRelapse Management in Multiple Sclerosis: Corticosteroids Remain the Linchpin of Therapies
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/relapse-management-in-multiple-sclerosis-corticosteroids-remain-the-linchpin-of-therapies/32084/Several modalities are available for the treatment of multiple sclerosis relapse, including corticosteroids, intravenous immunoglobulins, and therapeutic apheresis.Going Off the Grid to a Noninsurance-Based Practice
https://practicalneurology.com/diseases-diagnoses/headache-pain/going-off-the-grid-to-a-noninsurance-based-practice/30218/A personal journey of surviving and thriving.Special Report: 2023 Neurology Drug & Device Approvals
https://practicalneurology.com/diseases-diagnoses/imaging-testing/special-report-2023-neurology-drug-device-approvals/32081/A quick reference for the drugs and devices for neurologic conditions that received approval from the Food and Drug Administration last year.Myasthenia Gravis
https://practicalneurology.com/diseases-diagnoses/neuromuscular/myasthenia-gravis/31814/More treatments for myasthenia gravis are on the way.In-house or Outsourced Billing: What to Know to Make a Choice or a Change
https://practicalneurology.com/columns/practice-management/in-house-or-outsourced-billing-what-to-know-to-make-a-choice-or-a-change/30809/There are pros and cons to each method. Research and preparation are essential to decision-making.Dementia
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/dementia/30629/Untangling the Clinical Challenges